Casdin Alexander W.
Known title: DirectorCIK: 0001455228
Casdin Alexander W.'s purchase track record
How the stock did after each of Casdin Alexander W.'s open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
Purchases measured
4
of 4 since December 15, 2022
Stock higher 6 months later
50%
3 months: 75%
Median 6-month return
-0.4%
3 months: +10.7%
Beat the S&P 500
50%
median -8.8% vs. index
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 5/21/2024 | ERAS | $182K | +17.9% | +18.7% | +11.2% |
| 12/4/2023 | ERAS | $50K | +39.9% | +53.6% | +15.6% |
| 4/10/2023 | ERAS | $55K | +3.5% | -19.6% | +5.5% |
| 12/15/2022 | ERAS | $97K | -32.3% | -41.9% | +13.6% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| ERAS | ▲ Buy | Open Market | 80,000 | $182K | 5/21/2024 | View on chart |
| ERAS | ▲ Buy | Open Market | 30,000 | $50K | 12/4/2023 | View on chart |
| ERAS | ▲ Buy | Open Market | 20,000 | $55K | 4/10/2023 | View on chart |
| ERAS | ▲ Buy | Open Market | 20,000 | $97K | 12/15/2022 | View on chart |
| ERAS | ▼ Sell | Other | 750,000 | $0 | 7/1/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 8, 2026
Erasca Faces Verastem Competition Amid Clinical Updates
Recent analysis highlights that Verastem's upcoming clinical data and commercial launch present a competitive challenge for Erasca. While Erasca's Revolution approval has reduced some development risk, the market is watching how the company navigates this new competitive landscape. The stock currently trades near significant support levels, reflecting cautious sentiment as investors assess these developments.
Erasca Faces Verastem Competition Amid Clinical Updates. Recent analysis highlights that Verastem's upcoming clinical data and commercial launch present a competitive challenge for Erasca. While Erasca's Revolution approval has reduced some development risk, the market is watching how the company navigates this new competitive landscape. The stock currently trades near significant support levels, reflecting cautious sentiment as investors assess these developments.